MedicineNews.net - Medical Updates

ARCTIC trial in third-line non-small cell lung cancer: Durvalumab monotherapy showed a clinically-meaningful reduction in the risk of death compared to chemotherapy

Results from the phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer ( NSCLC ) who have received at least two prior treatments, were announced. This rand ... read article

Pembrolizumab improves overall survival and progression-free survival as first-line treatment for squamous non-small cell lung cancer (NSCLC) in KEYNOTE-407 trial

The pivotal phase 3 KEYNOTE-407 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Carboplatin-paclitaxel or nab-Paclitaxel, as first-line treatment for metastat ... read article

Mvasi, a biosimilar to the cancer drug Avastin, approved from FDA for certain colorectal, lung, brain, kidney and cervical cancers

The FDA ( Food and Drug Administration ) has approved Mvasi ( Bevacizumab-awwb ) as a biosimilar to Avastin ( Bevacizumab ) for the treatment of multiple types of cancer. Mvasi is the first biosimil ... read article

Update on European application for Keytruda in combination with Pemetrexed and Carboplatin for first-line treatment of nonsquamous non-small cell lung cancer

Merck ( MSD ) has withdrawn its European application for Keytruda ( Pembrolizumab ) in combination with Pemetrexed and Carboplatin as a first-line treatment for metastatic nonsquamous non-small cell l ... read article

Keytruda in recurrent or metastatic head and neck cancer, FDA granted priority review

The FDA ( Food and Drug Administration ) has accepted for review the supplemental Biologics License Application ( sBLA ) for Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the treatment of pati ... read article

Giotrif, overall survival benefit for patients with EGFR mutation-positive non-small cell lung cancer

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion for an update to the European label for Giotrif ( Afatinib ), strengt ... read article

Selumetinib, a MEK inhibitor, in combination with Dacarbazine does not effective in uveal melanoma

The phase 3 SUMIT study of Selumetinib in combination with Dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. Th ... read article

NICE has recommended Vargatef in combination with Docetaxel, as a new treatment option for patients with locally advanced metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy

National Institute for Health and Care Excellence ( NICE ) in the UK, has recommended Vargatef ( Nintedanib ) in combination with Docetaxel for use within the National Health Service ( NHS ) in Englan ... read article

Keytruda, an anti-PD-1 therapy, in advanced non-small cell lung cancer

The supplemental Biologics License Application ( sBLA ) for anti-PD-1 therapy, Keytruda ( Pembrolizumab ), for the treatment of patients with advanced non-small cell lung cancer ( NSCLC ) whose diseas ... read article

Non-small cell lung cancer: Afatinib provides more than one year additional survival in patients with the most common type of EGFR mutation ( del19 ) compared to chemotherapy

Boehringer Ingelheim has announced results of the pre-specified individual, as well as the exploratory combined, analyses of two phase III trials ( LUX-Lung 3 and LUX-Lung 6 ). These data have demonst ... read article

Erlotinib plus Onartuzumab in advanced non-small cell lung cancer: METLung study stopped on lack of clinically efficacy

Roche has announced that an independent data monitoring Committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy. The study evaluated if ... read article

MK-3475 shows encouraging results in treating non-small cell lung cancer

MK-3475, an experimental cancer drug, has shown early potential as an effective treatment for patients with non-small cell lung cancer ( NSCLC ).Preliminary results of a phase 1B study of MK-3475 were ... read article

Risk of osteonecrosis of the jaw associated with Bevacizumab and Sunitinib

Treatment with Bevacizumab or Sunitinib may be a risk factor for the development of osteonecrosis of the jaw, particularly if a patient has previously received, or is treated concurrently with, bispho ... read article

Xgeva for preventing cancer-related bone injury, FDA approved

The FDA ( Food and Drug Administration ) has approved Xgeva ( Denosumab ) to help prevent skeletal-related events ( SREs ) in patients with cancer that has metastasized and damaged the bone. Skeletal- ... read article

Bevacizumab-based therapy extends survival beyond fourteen months in patients with advanced non-small cell lung cancer

New data have shown that Bevacizumab-based therapy provides a median overall survival of 14.6 months with a range of chemotherapies routinely used in clinical practice and in a broad population of pat ... read article